SCHEMBL24253053

SCHEMBL24253053

COc1ccc(CNc2cnnc3cc(-c4cc(Cl)ccc4OC(S)(S)S)ccc23)c(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
CYP1A2 P05177 14/20 0.40
CYP3A4 P08684 14/20 0.40
CYP2C19 P33261 13/20 0.40
TSHR P16473 11/20 0.40
CYP2C9 P11712 10/20 0.40
HSD17B10 Q99714 9/20 0.40
ALDH1A1 P00352 8/20 0.40
LMNA P02545 8/20 0.40
CLK4 Q9HAZ1 7/20 0.40
CYP2D6 P10635 12/20 0.38
MAPT P10636 3/20 0.38
HIF1A Q16665 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPK1 P28482 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451317 0.92 CYP1A2 (0.46) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL24252808 0.92 CYP1A2 (0.46) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL30451966 0.91 CNR1 (0.40) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL24252485 0.91 CNR1 (0.40) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL30467656 0.90 CNR1 (0.41) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL24252909 0.90 CNR1 (0.41) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL30467726 0.88 CYP1A2 (0.43) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL24252403 0.87 CNR1 (0.43) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL24252980 0.87 CYP1A2 (0.41) CNR1CNR2CYP1A2CYP3A4CYP2C19
SCHEMBL30467579 0.87 CYP1A2 (0.41) CNR1CNR2CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CNR1 2075/4885CNR2 1499/4885CYP1A2 2977/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 CNR1 2075/4885CNR2 1499/4885CYP1A2 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.